Clinical Trial Detail

NCT ID NCT03029832
Title A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-Based Therapy
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Genentech, Inc.
Indications

transitional cell carcinoma

Therapies

Atezolizumab

Atezolizumab + MOXR0916

Age Groups: senior adult

No variant requirements are available.